Condition
Hematologic Malignacies
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Enrolling By Invitation1
Not Yet Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04266093Enrolling By Invitation
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
NCT07696767Early Phase 1Not Yet Recruiting
Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation
NCT07270263Not ApplicableRecruiting
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Showing all 3 trials